{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT01517256: Phase 3 Interventional Completed Chronic Pain
(2009)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00053443: Phase 2 Interventional Completed HIV Infections
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT00597727: Phase 2 Interventional Completed Food Hypersensitivity
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01985191: Phase 1 Interventional Completed Neoplasm Malignant
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
SAR-405838 is an inhibitor of the interaction between the oncoprotein murine double minute 2 (MDM2) and p53. SAR-405838 was investigated in phase I clinical trials in patients with locally advanced/metastatic solid tumor with wild-type TP53 or with TP53 mutation prevalence below 40%. SAR-405838 had an acceptable safety profile with limited activity in patients with advanced solid tumors.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01779427: Not Applicable Interventional Withdrawn Traumatic Brain Injury (TBI)
(2013)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Senju Pharmaceutical is developing fonadelpar (also known as SJP-0035), a peroxisome proliferator activated receptor delta agonist as an ophthalmic solution. Fonadelpar was studied in phase III clinical trial in the USA for the treatment of patients with dry eye disease. This study was successfully completed. In addition, fonadelpar was involved in phase II clinical trial in the USA for the treatment of patients with moderate to severe corneal epithelial disorders. Besides, Senju Pharmaceutical also plans a phase II trial for corneal disorders in Japan.
Status:
Investigational
Source:
NCT01185080: Phase 2 Interventional Completed Allergic Rhinitis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01027234: Phase 1 Interventional Terminated Healthy
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:LANABECESTAT CAMSYLATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
